SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Seattle Genetics, Inc. Reports Data From Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-Line Hodgkin Lymphoma at American Society of Hematology Annual Meeting